NRx Pharmaceuticals Surpasses Expectations in Q4 2025 Results, Sets Stage for Pivotal Year Ahead
The latest conference call transcript from NRx Pharmaceuticals has revealed a transformative year for the company, with significant advancements in its development programs and a renewed outlook on profitability.
Dr. Jonathan Javitt, Founder, Chairman, and CEO of NRx, expressed optimism during the call, stating that 2025 was a "pivotal and transformative year" for the company. The HOPE Therapeutics subsidiary has demonstrated EBITDA-positive revenue growth, while the parent company has ended the year with $7.8 million in cash on hand.
The key highlight of NRx's development programs is the progress made on its Abbreviated New Drug application (ANDA) for preservative-free ketamine, known as KETAFREE. In August 2025, FDA approved the company's suitability petition for its proposed strength of preservative-free ketamine. Following this, the company filed the ANDA in September and received notification from FDA that it would review the file without significant deficiencies.
In a recent update, FDA notified NRx of a preliminary determination of bioequivalence to the reference branded drug, Ketalar. This is a crucial milestone for KETAFREE's approval, with the company having manufactured three registration batches in anticipation of summer 2026 approval. Additionally, NRx has submitted a citizen petition seeking to have benzethonium chloride, a toxic preservative included in all currently approved ketamine products, removed from all presentations of ketamine.
The submission of this petition highlights NRx's commitment to innovation and patient safety. A detailed toxicology report posted on the public record casts doubt on the assumed safety of benzethonium chloride, emphasizing the need for its removal from all drug presentations. Notably, this preservative is not categorized by FDA as Generally Recognized as Safe (GRAS).
The company's patent application to protect intellectual property surrounding KETAFREE demonstrates its dedication to safeguarding its innovative products. With a low cash burn and potential profitability on the horizon, NRx Pharmaceuticals seems poised for success in 2026.
